| Is there a need for new therapies for rheumatoid arthritis? | |
| | |
MedLine Citation:
|
PMID: 15693109 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although traditional disease modifying and biological response modifying agents are very useful in controlling disease activity, limiting disease progression, and improving function in patients with rheumatoid arthritis (RA), very few patients achieve full remission from treatment with these medications either when given alone or in combination. The combination of methotrexate (MTX) and the biologic agents appears to provide the highest level of response that is presently achievable. A contributory factor to the limited benefit from such regimens in some patients is that patients are unable to continue these medications, either because of lack of efficacy or adverse events. As even the most effective currently available interventions are not ideal in all patients, the search for new therapies -- which may be able to improve on the best possible clinical effect achievable to date -- is therefore necessary, desirable, and justified. One approach to new treatment paradigms for RA is to evaluate the role of B cells in RA and the effect of targeted B cell therapy on clinical outcome, based on a sound rationale and encouraging emerging clinical evidence. This approach will be examined in this and the following articles. |
| | |
Authors:
|
Roy M Fleischmann |
Related Documents
:
|
8883429 - Margaret holroyd prize essay. a patient-centred approach to evaluation and treatment in... 83619 - Self-conversion of supraventricular tachycardia by rapid atrial pacing. 18266209 - The presence of jak2v617f in primary myelofibrosis or its allele burden in polycythemia... 2681899 - Clinical studies of polymyalgia rheumatica. a proposal of diagnostic criteria. 11324779 - Health-related quality of life of patients with psoriatic arthritis: a comparison with ... 2313669 - Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rh... 15730589 - Ossification of the ligamentum flavum as a result of fluorosis causing myelopathy: repo... 7377279 - Optometric therapy of divergence excess strabismus. 7305949 - Deficient phosphorylation of mannose residues of mannan in fibroblasts of patients with... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Journal of rheumatology. Supplement Volume: 73 ISSN: 0380-0903 ISO Abbreviation: J Rheumatol Suppl Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2005-02-04 Completed Date: 2005-04-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7806058 Medline TA: J Rheumatol Suppl Country: Canada |
Other Details:
|
Languages: eng Pagination: 3-7; discussion 29-30 Citation Subset: IM |
Affiliation:
|
University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas, USA. royfleischmann@radiantresearch.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antirheumatic Agents
/
therapeutic use Arthritis, Rheumatoid / immunology, therapy* B-Lymphocytes / immunology Drug Therapy, Combination Humans Immunologic Factors / therapeutic use Rheumatology / trends* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 0/Immunologic Factors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitt...
Next Document: Common mechanisms in immune-mediated inflammatory disease.